Data quality issues at advanced old age, such as incompleteness of registration of vital events and age misreporting, compromise estimates of the death rates and remaining life expectancy at those ages. Following up on Horiuchi and Coale (Population Studies 36: 317-326, 1982), Mitra (Population Studies 38: 313-319, 1984, Population Studies 39: 511-512, 1985), and Coale (Population Studies 39: 507-509, 1985), we examine the conventional approaches to constructing life tables from data deficient at advanced ages and the two adjustment methods by the mentioned authors. Contrary to earlier reports by Horiuchi, Coale, and Mitra, we show that the two methods are consistent and useful in drastically reducing the estimation errors in life expectancy as compared to the conventional approaches, i.e., the classical open age interval model and extrapolation of the death rates. Our results suggest complementing the classical estimates of life expectancy by adjustments using Horiuchi-Coale, Mitra, or other appropriate methods and avoiding the extrapolation method as a tool for estimating the life expectancy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797569 | PMC |
http://dx.doi.org/10.1186/s41118-018-0029-7 | DOI Listing |
Sci Rep
January 2025
Department of Gynecology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750002, Ningxia, China.
Hypertensive disorders of pregnancy (HDP) are significant global health issues. This study utilized data from the Global Burden of Disease Study 2021 to analyze trends in incidence, prevalence, and Disability-Adjusted Life Years (DALY) associated with HDP across 204 countries from 1990 to 2021. The analysis employed estimated annual percentage changes and an age-period-cohort model, stratifying data by age, year, geographical region, and sociodemographic index (SDI).
View Article and Find Full Text PDFLancet Oncol
January 2025
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. Electronic address:
Background: CMG901 is a novel first-in-class antibody-drug conjugate with a humanised anticlaudin 18.2 antibody linked to microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the antitumour activity and safety of CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer and other solid tumours.
View Article and Find Full Text PDFNeuron
January 2025
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. Electronic address:
As global life expectancy increases, age-related brain diseases such as stroke and dementia have become leading causes of death and disability. The aging of the neurovasculature is a critical determinant of brain aging and disease risk. Neurovascular cells are particularly vulnerable to aging, which induces significant structural and functional changes in arterial, venous, and lymphatic vessels.
View Article and Find Full Text PDFTissue Cell
January 2025
Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:
Malignant pheochromocytomas are infrequent tumors that have a poorer prognosis compared to their benign counterparts. The administration of chemotherapy to patients with pheochromocytoma can result in adverse side effects and a reduced life quality. Alternative and more targeted treatment strategies, such as gene therapy significantly improve the patients' survival rate and life expectancy.
View Article and Find Full Text PDFPLoS One
January 2025
Institute for Palliative Care, Region Skåne and Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Background: Large, international cohort studies generate high-level evidence, but are resource intense. In end-of-life care such studies are scarce. Hence, planning for future studies in terms of data on screening, recruitment, retention and survival remains a challenge.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!